Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01238965 · ClinicalTrials.gov registry record · Phase 1

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

A Phase 1 study, sponsored by University of Southern California.

Terminated
Registry status
Phase 1
Development phase
7
Enrollment target

NCT01238965: Clinical Trial Phase 1 study, sponsored by University of Southern California.

NCT01238965 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01238965, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.

TERMINATED
Registry status
Phase 1
Development phase
7 participants
Enrollment target

Study Summary

Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with fluorouracil and leucovorin calcium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best dose of giving panobinostat, fluorouracil, and leucovorin calcium together in treating patients with stage IV colorectal cancer who did not respond to previous fluorouracil-based chemotherapy.

Interventions

  • DRUG panobinostat
  • PROCEDURE biopsy
  • DRUG fluorouracil
  • DRUG leucovorin calcium
  • GENETIC reverse transcriptase-polymerase chain reaction

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2010-10
Est. Completion 2015-04
Phase Phase 1
University of Southern California

617 total trials

Why NCT01238965 stopped before completion

NCT01238965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 5 interventions - of which panobinostat is the first listed.

NCT01238965 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01238965 about?

NCT01238965 is a clinical study titled "Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy". Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gi...

What is the current status of trial NCT01238965?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-10. Estimated completion is 2015-04.

What interventions are being tested in trial NCT01238965?

The interventions under investigation include: panobinostat (DRUG), biopsy (PROCEDURE), fluorouracil (DRUG), leucovorin calcium (DRUG), reverse transcriptase-polymerase chain reaction (GENETIC).

Who is sponsoring clinical trial NCT01238965?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01238965's enrollment target sits among peer trials

7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01238965, the US trial registry maintained by the National Library of Medicine. NCT01238965 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.